F S&P 500
5,539.25 +2.25 (+0.04%) F Dow Jones
39,507.00 -19.00 (-0.05%) F Nasdaq
19,992.50 +20.25 (+0.10%) E-mini Russell 2000 Index Futur
2,044.30 -0.60 (-0.03%) Petróleo
80.95 +0.12 (+0.15%) Oro
2,326.00 -4.80 (-0.21%)
Helix BioPharma Corp. (HBPCF)
Helix BioPharma Corp.
401 Bay Street
Suite 2704 PO Box 4
Toronto, ON M5H 2Y4
Canada
905-841-2300
https://www.helixbiopharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 9
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Jacek Antas | Chairman & CEO | 73.66k | N/D | N/D |
| Mr. Praveen Kumar Varshney F.C.A., FCA, FCPA, LLB | CFO & Corporate Secretary | N/D | N/D | 1966 |
| Dr. Gabrielle M. Siegers M.A., Ph.D. | Head of R&D | N/D | N/D | N/D |
| Dr. Srikanth Sola | Chief Strategy Officer | N/D | N/D | N/D |
| Dr. Christof Boehler | Chief Business Development Officer | N/D | N/D | N/D |
Descripción
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.
Gestión corporativa
La calificación ISS Governance QuickScore de Helix BioPharma Corp. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
